Orion Oyj (ORINY)

Market Cap	10.90B +32.1%
Revenue (ttm)	2.22B +22.5%
Net Income	587.41M +51.7%
EPS	4.18 +51.5%
Shares Out	n/a
PE Ratio	18.56
Forward PE	18.07
Dividend	0.51 (1.36%)
Ex-Dividend Date	Mar 26, 2026

Volume	105
Average Volume	219
Open	37.99
Previous Close	n/a
Day's Range	37.99 - 37.99
52-Week Range	25.95 - 42.75
Beta	0.36
RSI	48.98
Earnings Date	Apr 23, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 4,029
• Stock Exchange: OTCMKTS
• Ticker Symbol: ORINY

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.

Financial numbers in EUR